Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment (Q45115848)

9 December 2017

title

Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment (English)

1 reference

9 December 2017

1 reference

Gisela Kobelt

1

1 reference

9 December 2017

Ingrid Lekander

2

1 reference

9 December 2017

Andrea Lang

3

1 reference

9 December 2017

Bernd Raffeiner

4

1 reference

9 December 2017

Costantino Botsios

5

1 reference

9 December 2017

Pierre Geborek

6

1 reference

9 December 2017

publication date

8 July 2011

1 reference

International Journal of Technology Assessment in Health Care

9 December 2017

published in

1 reference

9 December 2017

volume

27

1 reference

9 December 2017

issue

3

1 reference

9 December 2017

page(s)

193-200

1 reference

Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Mortality in rheumatoid arthritis patients with disease onset in the 1980s

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Ten arguments for a societal perspective in the economic evaluation of medical innovations

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

The links between joint damage and disability in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462311000195

7 January 2021

10.1017/S0266462311000195

Identifiers

DOI

1 reference

release_b7igmhhl7vgnnjr3f4s72hzjp4

9 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b7igmhhl7vgnnjr3f4s72hzjp4

24 November 2022

mapped directly with Wikidata item

1 reference